Europe Heparin Market, by Product Type (Low Molecular Weight Heparin, Unfractionated Heparin, Ultra Low Molecular Weight Heparin), by End User (Hospitals, Blood and Stem Cell Bank, Others (Laboratories, Acute Care Centers)) and by Country (Germany, France, U.K., Italy, Spain, Russia, The Netherlands, Poland, Switzerland, Sweden, and Rest of Europe) is estimated to be valued at US$ 3,459.3 billion in 2023 and is expected to exhibit a CAGR of 6.4% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
The advent of expansions to international markets can provide lucrative growth opportunities for players. Thus, key market players are focused on adopting growth strategies such as product launch, which will drive the Europe heparin market. For instance, On October 4, 2022, Laboratorios Farmaceuticos ROVI SA presented Glycopepton Biotech, S.L., laboratory to produce compounds of high technological value a joint venture with Càrniques Celrà, S.L., provides storage facilities and Grupo Empresarial Costa, S.L., operates as a holding company, spain that involves the creation of one of the first national structures for self-sufficiency in heparins. The project involves the construction of a facility at the Industrial Logistics Platform of Fraga (Huesca), which will produce compounds of high biological value that derive from the intestinal mucosa of pigs.
Europe Heparin Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
The COVID-19 pandemic caused an extraordinary burden on the healthcare system and patient care and dramatically impacted the delivery of medical services
In order to limit the spread of the infection many governments imposed measures, mostly based on personal distancing or declared states of emergency.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another.
COVID-19 had a moderate impact on the Europe heparin market. For instance, according to an article published in the National Center for Biotechnology Information, on October 11, 2022, Heparin-induced extracorporeal LDL/fibrinogen precipitation in apheresis, blood cells are first separated from plasma in extracorporeal circulation, then 400,000 units of unfractionated heparin are added to the plasma and the pH is lowered using an acetate buffer. This is the isoelectric point for optimal precipitation of apolipoproteins from low-density lipoproteins cholesterol, lipoprotein and very low-density lipoproteins which are precipitated in a precipitation filter with fibrinogen. Excess heparin is adsorbed and bicarbonate dialysis rebalances the pH. The patients' blood cells are reinfused in parallel with saline. The duration of the treatment- on average 2 hours- can be shortened or extended according to an individual needs.
Europe Heparin Market: Key Developments
Business sales can help the growth of the Europe heparin market. For instance, on February 21, 2023, Laboratorios Farmaceuticos ROVI SA, Spain-based pharmaceutical company published in the annual report 2022 stating sales of the heparin franchise (Low Molecular Weight Heparins (LMWH) and other heparins increased by 9% to US$ 28 millions Sales of the enoxaparin, biosimilar increased 23% to US$ 16 millions. The increase is due to the research and development.
On October 4, 2022, Laboratorios Farmaceuticos ROVI SA, Spain-based pharmaceutical company and Glicopepton Biotech, laboratory to produce compounds of high technological value combines in the research into low-molecular-weight heparins (LMWH) with the track records of Càrniques Celrà and Grupo Empresarial Costa, two major companies in the livestock and meat industry in Spain. LMWHs are anticoagulant drugs used to prevent and treat venous thromboembolic disease. They are a biological product whose raw material is obtained from the intestinal mucosa of pigs. This project seeks both the creation of economic and technological value, transforming pig mucosa into a high-value-added product like heparin, and the development of new animal food supplements and fertilisers.
Browse 20 Market Data Tables and 28 Figures spread through 199 Pages and in-depth TOC on “Europe Heparin Market”- Forecast to 2030, Europe Heparin Market, by Product Type (Low Molecular Weight Heparin, Unfractionated Heparin, Ultra Low Molecular Weight Heparin), by End User (Hospitals, Blood and Stem Cell Bank, Others (Laboratories, Acute Care Centers)) and by Country (Germany, France, U.K., Italy, Spain, Russia, The Netherlands, Poland, Switzerland, Sweden, and Rest of Europe)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/europe-heparin-market-3960
Key Takeaways of the Europe Heparin Market:
- The Europe Heparin market is expected to exhibit a CAGR of 6.4% during the forecast period. European Society of Cardiology on April 21, 2023 explained about the specific recommendations are provided for thrombocytopenic patients. Coronary artery bypass grafting is not advised if the platelet count is <30,000 and <50,000/μl, respectively, although diagnostic angiography can be undertaken with radial access and close attention to haemostasis, adjusted heparin dosing and platelet transfusion beforehand if <20,000/μl. This use of heparin can be considered as the driver for growth of Europe heparin market,
- Among End User, the hospital segment is expected to grow in the Europe heparin market over the forecast period due to the greatest number of treatments provided in the region. For instance, On April 21, 2023, European Society of Cardiology,European journal explained hospitalised or prolonged bed-rest patients should receive prophylactic low molecular weight heparin and patients with major abdominal or pelvic surgery should receive extended prophylaxis with low molecular weight heparin for 4 weeks postoperatively. There may be a role for primary prevention in select high-risk ambulatory patients.
- Among country, U.K. is expected to be the dominant region in the Europe pharmaceutical drugs market, owing to the increasing research. The New England Journal of Medicine on January 19, 2023, explained in patients with extremity fractures that had been treated operatively or with any pelvic or acetabular fracture, thromboprophylaxis with aspirin was non-inferior to low-molecular-weight heparin in preventing death and was associated with low incidences of deep-vein thrombosis and pulmonary embolism and low 90-day mortality
- Major players operating in the Europe heparin market include Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun Melsungen AG, Baxter International Inc, GlaxoSmithKline plc, Bayer AG, Anselm Pharmaceuticals, Bristol-Myers Squibb Co, Dr. Reddy’s Laboratories Ltd, Fresenius SE & Co. KGaA, Leap Labchem Co, LEO Pharma A/S, Sanofi S.A, Syntex S.A., Teva Pharmaceutical Industries Ltd, United Biotech (P) Ltd, Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, and Intrapharm Laboratories.
